Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4831199 | 0.85 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3CHRNB4CHRNA3 | |
| SCHEMBL3962571 | 0.80 | LMNA (0.37) | — | |
| SCHEMBL1795653 | 0.78 | CHRNB4 (0.50) | SLC6A2SLC6A4SLC6A3CHRNB4CHRNA3 | |
| SCHEMBL1794388 | 0.78 | CHRNB4 (0.50) | SLC6A2SLC6A4SLC6A3CHRNB4CHRNA3 | |
| SCHEMBL1797151 | 0.78 | CHRNB4 (0.50) | SLC6A2SLC6A4SLC6A3CHRNB4CHRNA3 | |
| SCHEMBL1797148 | 0.78 | CHRNB4 (0.50) | SLC6A2SLC6A4SLC6A3CHRNB4CHRNA3 | |
| SCHEMBL1795410 | 0.78 | CHRNB4 (0.50) | SLC6A2SLC6A4SLC6A3CHRNB4CHRNA3 | |
| SCHEMBL13403267 | 0.77 | CHRNB4 (0.49) | SLC6A2SLC6A4SLC6A3CHRNB4CHRNA3 | |
| SCHEMBL4781846 | 0.74 | DPP4 (0.44) | SLC6A2SLC6A4SLC6A3CHRNB4CHRNA3 | |
| SCHEMBL14873238 | 0.74 | IDO1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335670-B2 | Derivatives of N-[heteroaryl(piperidine-2-yl) methyl]benzamide, preparation method thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2008-02-26 | — | — | US | disclosed |
| US-20060223886-A1 | Derivatives of N-[heteroaryl(piperidine-2-yl) methyl]benzamide, preparation method thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223886-A1 | Derivatives of N-[heteroaryl(piperidine-2-yl) methyl]benzamide, preparation method thereof and application of same in therapeutics | GABRE, SNCA, CHRNA5 | SLC6A2 936/4885SLC6A4 2062/4885SLC6A3 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.